Following the announcement of a worldwide distribution deal in May with Dutch company, Medical Measurement Systems, Crospon has completed its start-up activities for EndoFLIP and has now gone into commercial production.
Crospon develops leading edge minimally invasive medical devices for monitoring, diagnosis and therapy in the gastroenterology area.
Announcing the completion of the first shipment, John O’Dea, CEO, Crospon said, “The shipment marks a real milestone both Crospon and EndoFLIP. We as a team at Crospon have been working towards this target for the last two years. I would like to take this opportunity to thank all of the staff at Crospon who have each played an integral part in bringing the company to this point. We look forward taking to the next steps in extending the application of the EndoFLIP platform technology into the Bariatric Surgery marketplace in the coming year.”
The EndoFLIP tool which is pending FDA approval was designed by Crospon to provide a more physiologically relevant diagnostic test for gastroesophageal reflux disease (GERD). Chronic GERD is a prevalent disorder reaching epidemic proportions worldwide that manifests itself as severe heartburn caused by stomach acid refluxing up into the oesophagus.
Crospon’s development of the EndoFLIP system was recently recognised with the 2009 European Gastroenterology Technology Implementation of the Year Award, by Frost & Sullivan.
In January, Crospon announced that its EndoFLIP system had received CE Mark certification from the NSAI (National Standards Authority of Ireland), the Irish notified body in accordance with the European Medical Device Directive.
